businessbriefs
10:03in productionCh. 1 · Name and origin/ 10:03 · ceiling 15 min
Companies

Cipla

1935

Cipla built scale before science—and still runs on that engine.

Cipla is a vertically integrated Indian pharma firm whose scale emerged from wartime supply capability and sustained by broad therapeutic coverage—not IP-driven innovation or financial engineering.

CompaniesIndiaPhotographyMedicineIndia across the network →
Chapters & takeaways5
  1. 1:02
    Name and origin

    Cipla began as a locally rooted lab in 1935 and rebranded formally in 1984—its name change signals institutional maturation, not reinvention.

  2. 2:29
    Wartime scale

    WWII demand for quinine and B12 gave Cipla its first proof of scalable, compliant manufacturing—before India’s drug industry was regulated.

  3. 3:34
    What it makes, where it sells

    Cipla’s business model is geographic reach plus therapeutic breadth—not platform tech, data, or biologics.

  4. 4:59
    Size without metrics

    Being third-largest in India says nothing about profitability, export share, or domestic pricing power—only relative volume among peers.

  5. 6:30
    The outlier product

    Deferiprone in 1995 was a rare first-in-class launch—but the source gives no data on uptake, royalties, or follow-on innovation.

Worth your time?

Yes. Study the whole thing.

3.5/ 5
What works
  • global manufacturing footprint
  • therapeutic category focus
  • wartime scale precedent
  • regulatory navigation history
What does not
  • funding rounds
  • founder profiles
  • market share
  • valuation
Study it if
  • students of industrial policy
  • analysts of emerging-market manufacturing
  • historians of global health supply chains
Skip it if
  • investors seeking growth metrics
  • innovation strategists
  • biotech founders
The written brief1 min read

What the company or idea is

Cipla is an Indian multinational pharmaceutical company founded in 1935 in Mumbai as the Chemical, Industrial & Pharmaceutical Laboratories. It develops medications for respiratory, cardiovascular, arthritis, diabetes, depression, and paediatric conditions.

How it actually makes money

Cipla makes money by manufacturing and selling generic and branded pharmaceuticals across 86 countries. It operates 47 manufacturing sites, but the sources do not state its revenue, margins, pricing model, or whether it relies on volume, licensing, or public-sector tenders.

What works

Its global footprint (47 manufacturing sites, 86 countries) and historical capacity to deliver at scale—evidenced by becoming the largest Allied supplier of quinine and Vitamin B12 during WWII—demonstrate operational execution in regulated, logistics-intensive markets.

What does not

The sources say nothing about Cipla’s current profitability, R&D spend, patent strategy, regulatory setbacks, pricing controversies, or dependence on any single market or product. Its claim to be ‘third-largest in India’ is uncontextualised: no size metric (revenue, volume, market share) is given.

What to take from it

Cipla’s longevity reflects early vertical integration in active pharmaceutical ingredients (API), wartime procurement leverage, and consistent focus on therapeutic categories with high global disease burden—not innovation-led differentiation.

Is it worth your time

Yes—if you are studying how Indian pharma scaled globally through wartime supply contracts, early API mastery, and regulatory arbitrage—but only if you treat its self-description as a starting point, not evidence.

Same desk · Companies4 of 164
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
10:55
Air Canada1937Air Canada is Canada’s state-founded, privatised, hub-based flag carrier—large by fleet and passengers, anchored in Montreal, Toronto, and Vancouver, and embedded in Star Alliance. It carried 45.3 million passengers in 2025. It was founded in 1937 as Trans-Canada Air Lines, renamed in 1965, privatised in 1988, acquired Canadian Airlines in 2000, and filed for bankruptcy protection in 2003 before emerging in 2004.
10:34
Air France1933Air France is the French flag carrier, formed on 30 August 1933 via merger of five airlines. It operates from Charles de Gaulle Airport, served 201 destinations across 78 countries as of 2013, and held a politically critical role in West Berlin from 1950 to 1990. Since 2003, it has been a subsidiary of Air France–KLM — not an independent entity. Its revenue comes from scheduled passenger and cargo services. Its longevity reflects state support and geopolitical utility, not market resilience or innovation.
Up next in Business

Citroën

André-Gustave Citroën · 1919 · 11:47

Citroën invented the future of car engineering — then went broke building it.

Play nextBack to Companies
11:47